Amicus Therapeutics, Inc. provided earnings guidance for the year 2023. For the full-year 2023, the company anticipates total Galafold revenue growth between 12% and 17% at CER driven by continued underlying demand from both switch and treatment-naïve patients, geographic expansion, label extensions, the continued diagnosis of new Fabry patients, and commercial execution across all major markets, including the U.S., EU, U.K., and Japan.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.2 USD | +4.03% | +6.42% | -28.15% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.15% | 2.9B | |
+49.74% | 54.63B | |
-5.38% | 39.92B | |
+37.32% | 38.82B | |
+14.65% | 26.86B | |
-12.56% | 26.22B | |
-21.86% | 18.78B | |
+26.12% | 12.21B | |
+1.81% | 12.16B | |
+26.69% | 11.94B |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2023